Semaglutide is one of the most extensively studied peptides in metabolic research and among the most widely discussed compounds in the GLP-1 class. This article provides an educational overview of what the published scientific literature reports about semaglutide, its mechanism, and its regulatory position in Australia. All information below is provided strictly for research and informational purposes.
What is Semaglutide?
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone. It shares approximately 94% sequence homology with human GLP-1 and acts as a GLP-1 receptor agonist. Research literature notes it is produced using recombinant DNA technology combined with chemical modification, and that structural modifications — particularly albumin binding and stabilisation against DPP-4 enzyme degradation — extend its half-life to roughly one week, compared with minutes for native GLP-1.
Mechanism of interest
Scientific interest in semaglutide centres on its selective activation of the GLP-1 receptor. The published literature describes GLP-1 as a physiological regulator with several documented actions:
- Pancreatic signalling — GLP-1 receptor activation is associated with glucose-dependent insulin secretion and reduced glucagon secretion.
- Central appetite pathways — GLP-1 receptors are expressed in regions of the brain involved in appetite and satiety regulation.
- Gastric emptying — research documents an effect on the rate at which food passes through the stomach.
- Cardiovascular and renal receptors — GLP-1 receptors are also expressed in the heart, vasculature, kidney and immune system, and are studied in that context.
Semaglutide sits within a broader research class alongside tirzepatide (a dual GIP/GLP-1 agonist) and retatrutide (a GIP/GLP-1/glucagon triple agonist), which act on additional receptor targets.
What the research has reported
Semaglutide has an extensive clinical trial record. The STEP programme, a global Phase 3 development programme, enrolled approximately 4,500 adults and examined semaglutide at 2.4 mg once-weekly. The SELECT trial was a 68-week double-blind, randomised, placebo-controlled study conducted across 41 countries including Australia. Earlier programmes including SUSTAIN examined its use in type 2 diabetes. Research continues into GLP-1 receptor activation across metabolic, cardiovascular and other areas.
Regulatory status in Australia — important
This distinction matters more for semaglutide than for most compounds in this space. Semaglutide is TGA-approved and available in Australia as a prescription medicine. Approved products include Ozempic (approved for management of adults with type 2 diabetes mellitus), Wegovy (approved for chronic weight management, and subsequently for cardiovascular risk reduction in eligible patients), and Rybelsus (an oral formulation).
This means there is an established, regulated, prescribed pathway for semaglutide in Australia. Anyone seeking semaglutide for a medical purpose should speak with a qualified medical practitioner about the approved, prescribed product. A doctor can assess suitability, discuss known risks and precautions, and provide appropriate monitoring — none of which applies to research-grade material.
Material supplied for laboratory research is an entirely separate matter: research-grade semaglutide is supplied strictly as a research compound, is not the approved pharmaceutical product, is not a substitute for it, and is not for human use.
Important disclaimer
This article is provided for informational and laboratory-research purposes only. Research-grade semaglutide is supplied strictly as a research compound, for in-vitro laboratory research use only. It is not for human or animal consumption and is not a substitute for any TGA-approved medicine. Nothing in this article constitutes medical advice, nor a recommendation for use in humans. Always refer to current published literature, applicable regulations, and a qualified healthcare professional.